Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

I1-imidazoline receptors: an update

P Bousquet1, M Dontenwill, H Greney

  • 1Laboratoire de Pharmacologie Cardiovasculaire et Rénale, CNRS ERS 109, Faculté de Médecine, Université Louis Pasteur, Strasbourg, France.

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
|September 25, 1998
PubMed
Summary

The antihypertensive drug rilmenidine selectively targets I1-imidazoline receptors, reducing blood pressure without common side effects like sedation. This selectivity offers a new therapeutic approach for hypertension.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining structural modeling and deep learning to calculate the E. coli protein interactome and functional networks.

Nature communications·2026
Same author

Combining structural modeling and deep learning to calculate the <i>E. coli</i> protein interactome and functional networks.

bioRxiv : the preprint server for biology·2025
Same author

Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Impact of an automated report comparison tool on trainee report modification rate at a tertiary hospital.

Clinical radiology·2024
Same author

Searching for clinical trials in oncology: finding a path through the maze.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Area of Science:

  • Pharmacology
  • Neuroscience
  • Cardiovascular Medicine

Background:

  • The nucleus reticularis lateralis of the ventrolateral medulla (NRL/RVLM) is identified as the site of hypotensive action for imidazoline compounds like clonidine.
  • Imidazoline compounds bind to specific imidazoline-binding sites, distinct from alpha-adrenergic receptors, which are classified into I1 and I2 subtypes.
  • These imidazoline receptors are implicated in blood pressure regulation and pathological conditions such as hypertension.

Purpose of the Study:

  • To investigate the role of I1-imidazoline receptors in the hypotensive effects of clonidine-like drugs.
  • To evaluate rilmenidine, a novel antihypertensive agent, for its selectivity towards I1-imidazoline receptors.
  • To understand the mechanism behind rilmenidine's reduced side effect profile compared to clonidine.

Related Experiment Videos

Main Methods:

  • Functional studies assessing the hypotensive effects of drugs in the NRL region.
  • Radioligand binding assays using [3H]clonidine to quantify binding to imidazoline sites in human medullary preparations.
  • Comparative analysis of rilmenidine's selectivity for cerebral imidazoline receptors versus clonidine.

Main Results:

  • Clonidine-like drugs' hypotensive effects involve I1-imidazoline receptors, while side effects are linked to alpha2-adrenergic receptors.
  • Rilmenidine, an oxazoline analogue, acts as a selective I1-imidazoline receptor agonist.
  • Rilmenidine demonstrates greater selectivity for cerebral imidazoline receptors than clonidine, correlating with fewer side effects.

Conclusions:

  • Rilmenidine is the first drug demonstrating favorable selectivity between I1-imidazoline and alpha2-adrenergic receptors.
  • This selectivity allows for blood pressure reduction with minimal sedation and dry mouth.
  • Rilmenidine represents a promising new class of antihypertensive drugs with an improved side effect profile.